PRECIGEN Investors

Events

PRGN-2012 AdenoVerse Immunotherapy Virtual Fireside Chat Hosted by Cantor Fitzgerald

Mar 25, 2024 at 1:00 PM EDT

Hosted by Jennifer Kim, Biotechnology Analyst at Cantor Fitzgerald, the virtual fireside chat will include discussion of the investigational PRGN-2012 AdenoVerse™ immunotherapy for the treatment of recurrent respiratory papillomatosis (RRP). Participants will include Helen Sabzevari, PhD, President and CEO of Precigen, and Clint T. Allen, MD, Principal Investigator, Section on Translational Tumor Immunology at the National Institutes of Health (NIH), and a lead investigator for the PRGN-2012 clinical study. The call is available to institutional clients of Cantor Fitzgerald.

Supporting Materials